Additionally, GC-4-mediated blocking of N-cadherin engagement between human CD34+ CML cells and stromal cells increased tumour cell sensitivity to imatinib, demonstrating a potential therapeutic strategy to overcome tyrosine kinase inhibitor resistance [131]. The gene discussed is CDH2; the disease is neoplasm.